Media Coverage

David F Fischer on target screening


Drug Target Review editor Steve Bremer asks David F Fischer, Executive Director Biology at Charles River, for his views on target discovery and validation in drug discovery.

Mouse Models Move Asian Markets


Asia is emerging as the next hot market for research animals. Now nearly half of the global market for mouse models is dominated by China, Singapore, Malaysia, and India. Terry Fisher of Charles River discusses with Lab Animal magazine.

Good Assays for Bad Immunogenicity


Immunogeneic assays are a necessity in the development of biotherapeutics. However, they pose daunting developmental challenges. Sebastien Boridy, PhD, Research Scientist of Immunogenicity at Charles River discusses in GEN.

Are You Sure Your Lab Is Clean?


Are you sure your lab is clean? Joan O’Malley, Manager of the Microbiology Department at Charles River, provides tips for making sure your lab disinfectants are working, from selecting the right media to not cross-fertilizing.

Mass Spectrometry Measures Up to Analytical Challenges


Despite limitations, mass spectrometry is having an impact on biologic drug development and manufacturing. Mario DiPaola, Scientific Director at Charles River, discusses the importance of mass spectrometry in BioPharm International.

Phenotypic Screens Take Atypical Course


To develop a disease-relevant phenotypic assay, Charles River developed primary cell-based assays of fibroblasts from skin biopsies of patients. Jeroen DeGroot, PhD, Senior Director of Biology, discusses the use of phenotype screens in scleroderma research in GEN.

Bridging the Translational Divide in Cognitive Research


Recently, there have been important advances in the application of touch-sensitive screens for testing cognitive behavior in several animal species. Maksym Kopanitsa, PhD, Head of Translational Biology at Charles River, discusses in Drug, Discovery and Development.

Microsampling: Where are we now?


Microsampling is now part of many companies’ workflows within the research and laboratory space and is becoming part of our day-to-day language in bioanalysis and clinical development. Tim Sangster, Head of Bioanalysis and Immunology at Charles River, provides an update on the current state of microsampling.

Displaying results 1-10 (of 69)
 |<  < 1 - 2 - 3 - 4 - 5 - 6 - 7  >  >|